Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg have identified a previously undocumented, organ-specific ...

Two-Part Dose Escalation and Expansion Trial Will Evaluate Efficacy and Safety of BYON4228 Alone and in Combination with Pembrolizumab NIJMEGEN, The ...

Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces the completion of ...

Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private ...

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall surviva ...

Basel: Roche has announced that a US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) discussed ...

The ODAC provides the FDA with independent opinions and review of safety and efficacy data from outside medical experts, though the recommendations are not binding. The FDA's evaluation of this ...

A Form 8-K outlining the full terms of the new credit facility will be filed with the Securities and Exchange Commission.

Victoria's Royal Jubilee adopts bispecific T-cell engagers, which show great promise, according to Island Health ...